Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)

Abstract

INTRODUCTIONReporting and sharing pharmacogenetic test results across clinical laboratories and electronic health records is a crucial step toward the implementation of clinical pharmacogenetics, but allele function and phenotype terms are not standardized. Our goal was to develop terms that can be broadly applied to characterize pharmacogenetic allele function and inferred phenotypes.MATERIALS AND METHODSTerms currently used by genetic testing laboratories and in the literature were identified. The Clinical Pharmacogenetics Implementation Consortium (CPIC) used the Delphi method to obtain consensus and agree on uniform terms among pharmacogenetic experts.RESULTSExperts with diverse involvement in at least one area of pharmacogenetics (clinicians, researchers, genetic testing laboratorians, pharmacogenetics implementers, and clinical informaticians; n=58) participated. After completion of five surveys, consensus (>70%) was reached with 90% of experts agreeing to the final sets of pharmacogenetic terms.DISCUSSIONThe proposed standardized pharmacogenetic terms will improve the understanding and interpretation of pharmacogenetic tests and reduce confusion by maintaining consistent nomenclature. These standard terms can also facilitate pharmacogenetic data sharing across diverse electronic health care record systems with clinical decision support.

Allele Drop Out Conferred by a Frequent CYP2D6 Genetic Variation For Commonly Used CYP2D6*3 Genotyping Assays

“…The number of categories and the genotypes that belong to each category vary between PGx expert groups. Recently published data from Caudle et al regarding the standardization of terms for clinical PGx test results described five CYP2D6 metabolizing phenotype categories: ultrarapid (increased activity compared to rapid metabolizers), rapid (activity between that of ultrarapid and normal metabolizers), normal (fully functional activity), intermediate (activity between that of normal and poor metabolizers) and poor (little to no enzyme activity) [25]. Sample #7 was found to have a CYP2D6 genotype of *3/*41 .…”

Role of genetic testing in patients undergoing percutaneous coronary intervention

“…The frequencies of CYP2C19 polymorphisms in major ethnic groups are presented in Table 1[47]. The distribution of CYP2C19 genotypes allows for individuals to be classified as follows: Ultrarapid metabolizers (UMs), Rapid metabolizers (RMs), normal metabolizers (NMs), Intermediate metabolizers (IMs), Poor metabolizers (PMs) (Table 2) [47,53]. PMs have 2 LOF alleles, and IM have one copy of a LOF allele.…”

Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population

“…CYP2D6 gene is highly polymorphic, and to date, more than 140 alleles have been discovered (www.cypalleles.ki.se/CYP2D6.htm). The phenotypic expression of these alleles have been grouped as: poor metabolizers (PMs), intermediate metabolizers (IMs), normal metabolizers (NMs), rapid metabolizers (RMs) and ultrarapid metabolizers (UMs) using such probe drugs as debrisoquine, dextromethorphan, sparteine, tramadol and metoprolol [3–5]. Of these probe drugs, dextromethorphan (DEX) appears favoured as it is relatively accessible and well tolerated when compared to the others [6–8].…”